The startup develops nuclear radiation sensors and monitoring systems, including dosimeters, that provide in-vivo and real-time tracking of patient radiation doses during prostate brachytherapy. This technology enables healthcare professionals to enhance the precision of cancer treatments and improve patient outcomes by ensuring accurate radiation delivery.
Funding
$5.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
During prostate brachytherapy, accurately tracking radiation dosage in real-time and in-vivo is challenging, potentially leading to imprecise cancer treatments and suboptimal patient outcomes. Current methods lack the ability to provide immediate feedback on radiation exposure within the patient's body.
Solution
NU-RISE develops nuclear radiation sensors and monitoring systems designed for real-time, in-vivo tracking of radiation doses during prostate brachytherapy. Their dosimeters provide healthcare professionals with the ability to monitor radiation levels directly within the patient, enabling enhanced precision in cancer treatment delivery. By offering immediate feedback on radiation exposure, the technology supports clinicians in making informed decisions to optimize treatment plans and improve patient outcomes. The system aims to ensure accurate radiation delivery, minimizing potential side effects and maximizing the effectiveness of the brachytherapy procedure.
Target Audience
The primary customers are healthcare professionals, specifically radiation oncologists and brachytherapy specialists, involved in prostate cancer treatment.
Features
- Real-time, in-vivo radiation dose tracking
- Dosimeters designed for use during prostate brachytherapy